HOOKIPA Pharma (HOOKIPA Pharma) Debt-to-Equity : 0.06 (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is HOOKIPA Pharma Debt-to-Equity?

HOOKIPA Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $2.73 Mil. HOOKIPA Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $3.35 Mil. HOOKIPA Pharma's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $104.52 Mil. HOOKIPA Pharma's debt to equity for the quarter that ended in Mar. 2024 was 0.06.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for HOOKIPA Pharma's Debt-to-Equity or its related term are showing as below:

HOOK' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.09 Med: 0.07 Max: 0.12
Current: 0.07

During the past 7 years, the highest Debt-to-Equity Ratio of HOOKIPA Pharma was 0.12. The lowest was -0.09. And the median was 0.07.

HOOK's Debt-to-Equity is ranked better than
66.76% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs HOOK: 0.07

HOOKIPA Pharma Debt-to-Equity Historical Data

The historical data trend for HOOKIPA Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HOOKIPA Pharma Debt-to-Equity Chart

HOOKIPA Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.10

0.07

0.12

0.06

0.07

HOOKIPA Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.07	0.04	0.04	0.07	0.06

Competitive Comparison of HOOKIPA Pharma's Debt-to-Equity

For the Biotechnology subindustry, HOOKIPA Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HOOKIPA Pharma's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HOOKIPA Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where HOOKIPA Pharma's Debt-to-Equity falls into.

HOOKIPA Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

HOOKIPA Pharma's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.758	+	3.801)	/	89.857
	=	0.07

HOOKIPA Pharma's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.728	+	3.354)	/	104.522
	=	0.06

HOOKIPA Pharma (NAS:HOOK) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

HOOKIPA Pharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of HOOKIPA Pharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

HOOKIPA Pharma (HOOKIPA Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HOOKIPA Pharma Inc (NAS:HOOK) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

350 Fifth Avenue, 72nd Floor, Suite 7240, New York, NY, USA, 10118

Website

https://www.hookipapharma.com

HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.

Executives

Reinhard Kandera	director, officer: Chief Financial Officer	C/O HOOKIPA PHARMA INC., 430 EAST 29TH ST., 14TH FLOOR, NEW YORK NY 10016
Jorn Aldag	director, officer: Chief Executive Officer	C/O UNUM THERAPEUTICS INC., 200 CAMBRIDGE PARK DRIVE SUITE 3100, CAMBRIDGE MA 02210
Mary Theresa Coelho	director	52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Katia Schlienger	officer: Chief Medical Officer	350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118
Malte Peters	director	TANGO THERAPEUTICS, INC., 100 BINNEY STREET, UNIT 700, CAMBRIDGE MA 02142
Timothy P. Reilly	director	C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10018
Gilead Sciences Inc	10 percent owner	333 LAKESIDE DR, FOSTER CITY CA 94404
Igor Matushansky	officer: Chief Medical Officer	C/O HOOKIPA PHARMA INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Sofinnova Capital Vi Fcpr	10 percent owner	C/O SOFINNOVA PARTNERS, 17 RUE DE SURENE, PARIS XX 75008
Christine D. Baker	officer: Chief Business Officer	C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118
Jean-charles Soria	director	C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE SUITE 7240, NEW YORK NY 10118
Anders Lilja	officer: Sr. VP, Technical Development	C/O HOOKIPA PHARMA INC., 430 EAST 29TH ST., 14TH FLOOR, NEW YORK NY 10016
Klaus Orlinger	officer: Sr. VP, Research	C/O HOOKIPA PHARMA INC., 430 EAST 29TH STREET, 14TH FLOOR, NEW YORK NY 10016
Roman Necina	officer: Chief Technology Officer	C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118
Forbion Capital Fund Ii Cooperatief U.a.	10 percent owner	C/O HOOKIPA PHARMA INC., 430 EAST 29TH STREET, 14TH FLOOR, NEW YORK NY 10016